Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
Authors
Keywords
-
Journal
PHARMACOECONOMICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-19
DOI
10.1007/s40273-023-01320-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- (2023) Thomas Michaeli et al. BMJ-British Medical Journal
- Clinical benefit, development, innovativeness, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations
- (2023) Daniel Tobias Michaeli et al. JNCI-Journal of the National Cancer Institute
- Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology
- (2023) Daniel Tobias Michaeli et al. VALUE IN HEALTH
- Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors
- (2022) Daniel Tobias Michaeli et al. Therapeutic Innovation & Regulatory Science
- Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
- (2022) Aakash Desai et al. JAMA Network Open
- Value drivers of development stage biopharma companies
- (2022) Daniel Tobias Michaeli et al. European Journal of Health Economics
- Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
- (2022) Daniel Tobias Michaeli et al. INVESTIGATIONAL NEW DRUGS
- Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis
- (2022) Kerstin N Vokinger et al. LANCET ONCOLOGY
- Economic Cost and Sustainability of Oral Therapies in Precision Oncology
- (2022) Aakash P. Desai et al. JCO Oncology Practice
- Trends in Prescription Drug Launch Prices, 2008-2021
- (2022) Benjamin N. Rome et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021
- (2022) Daniel Tobias Michaeli et al. JOURNAL OF CLINICAL ONCOLOGY
- Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
- (2022) Daniel Tobias Michaeli et al. Applied Health Economics and Health Policy
- Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018
- (2022) Olivier J. Wouters et al. JAMA Network Open
- Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries
- (2022) Leah Z. Rand et al. PHARMACOECONOMICS
- Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020
- (2021) Patrick Liu et al. JAMA Network Open
- Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases
- (2021) Kao-Ping Chua et al. HEALTH AFFAIRS
- Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
- (2021) Benjamin N. Rome et al. JAMA Network Open
- Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe
- (2021) Kerstin N. Vokinger et al. JAMA Oncology
- Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018
- (2020) Inmaculada Hernandez et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs
- (2020) James D. Chambers et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
- (2020) Kerstin N Vokinger et al. LANCET ONCOLOGY
- Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany
- (2020) Victoria D. Lauenroth et al. HEALTH AFFAIRS
- Association Between Clinical Value and Financial Cost of Cancer Treatments: A Cross-Sectional Analysis
- (2020) Aaron P. Mitchell et al. Journal of the National Comprehensive Cancer Network
- The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs
- (2019) Inmaculada Hernandez et al. HEALTH AFFAIRS
- Competition and price among brand-name drugs in the same class: A systematic review of the evidence
- (2019) Ameet Sarpatwari et al. PLOS MEDICINE
- Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
- (2019) Kerstin N. Vokinger et al. HEALTH POLICY
- Trajectories of Injectable Cancer Drug Costs After Launch in the United States
- (2018) Noa Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
- (2017) Joseph C Del Paggio et al. LANCET ONCOLOGY
- Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure
- (2016) Caroline S. Bennette et al. HEALTH AFFAIRS
- Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer
- (2016) Scott D. Ramsey et al. JOURNAL OF CLINICAL ONCOLOGY
- Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries
- (2016) Daniele Mengato et al. Therapeutic Advances in Medical Oncology
- Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014
- (2016) Stacie B. Dusetzina JAMA Oncology
- Placebo effect of medication cost in Parkinson disease: A randomized double-blind study
- (2015) A. J. Espay et al. NEUROLOGY
- Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
- (2015) Todd Gammie et al. PLoS One
- Effectiveness, safety and costs of orphan drugs: an evidence-based review
- (2015) Igho J Onakpoya et al. BMJ Open
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Are survivors who report cancer-related financial problems more likely to forgo or delay medical care?
- (2013) Erin E. Kent et al. CANCER
- Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis
- (2013) Scott Ramsey et al. HEALTH AFFAIRS
- Pricing and reimbursement of orphan drugs: the need for more transparency
- (2011) Steven Simoens Orphanet Journal of Rare Diseases
- Medical Bankruptcy in the United States, 2007: Results of a National Study
- (2009) David U. Himmelstein et al. AMERICAN JOURNAL OF MEDICINE
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- (2009) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
- Commercial Features of Placebo and Therapeutic Efficacy
- (2008) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now